CLAIMS

1. A compound of formula (I)

[MCL-1 ligand moiety] – linker – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:


,

,

,

,

,

,

or

in which

M is O, S or NH, or is absent;

 indicates attachment to **R[18]** of the linker;

R[22] is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl; and

R[29] is hydrogen or Me

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl;

in which **[MCL-1 ligand moiety]** is a compound of Formula (A1), (A2), (A3) or (A4):



(A1)

,



(A2)

,



(A3)

or



(A4)

in which

 is a single bond or a double bond;

each **Z_2** is independently N or C, in which when **Z_2** is N, then  is a single bond; and when **Z_2** is C, then  is a double bond**;**

each **R[9]** is independently -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or P(O)$(OH)_2$,

each **R[11]** is independently H, halogen or C_1-C_6 alkyl,

R[8] is C_1-C_6 alkyl substituted with a piperazine;

in each of Formula (A1) and Formula (A4), one of **R[10]** and **R[30]** is H and the other of **R[10]** and **R[30]** is -$C_{2\text{-}5}$ alkyl-O-R^{13} , -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13} , in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally

substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R^{12} is  ,  ,  or  ,

each **R^{33}** is independently H, **R^{19}**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R^{31} is -C_{2-5} alkyl-O-R^{13} , -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13} , in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

each **R^{32}** is independently H,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  ,


,

,

,

,

or

,

in which **R[20]** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), or -CH_2-O-bromobenzaldehyde, in which p is 1-5;

R[34] is C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

R[35] is  or  ; and

R[19] is a bond connected to **R[14]** of the linker, in which each of Formula (A1), Formula (A2), Formula (A3) and Formula (A4) contains a single **R[19];**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R[14] is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R[15] is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-C_{1-6} alkyl-, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -$C_{1\text{-}6}$ alkyl, -$C_{1\text{-}6}$ alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

2. A compound according to Claim 1, in which **[ligase ligand moiety]** is:

(a)



,


,


or


; or

(b)



or


; or

(c)


R22
M
O
N
O
N
L'
O

or


M
R22
O
N
O
N
L'
O

; or

(d)


N
H
O
N
O
HN
O

,


O
O
N
O
HN
O

,


MeO
O
O
N
O
NH
O

,


N
O
O
N
O
NH
O

,


NH2
O
O
N
O
NH
O

,


NHMe
O
O
N
O
NH
O

,


NMe2
O
O
N
O
NH
O

,


H2N
O
O
N
O
NH
O

,


MeHN
O
O
N
O
NH
O

,



,


,


,


,


or


; or

(e)



or


; or

(f)



or


.

3. A compound according to Claim 1 or 2, in which **R^{22}** is hydrogen, halogen, -OMe, -NH_2, -NHMe, -NMe_2, or piperidine; optionally in which **R^{22}** is hydrogen, -OMe, -NH_2, -NHMe, -NMe_2, or piperidine; further optionally in which **R^{22}** is hydrogen.

4. A compound according to Claim 1, 2 or 3, in which:

R^{16} is -$C_{1\text{-}6}$ alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, -$(C_2H_4\text{-}O)_x$, -$(C_3H_6\text{-}O)_x$, or is absent

R^{18} is -$C_{1\text{-}6}$ alkyl, cycloalkyl, -CH_2-NH-C(O)-, heterocycloalkyl, or is absent; optionally in which **R^{18}** is -C1-6 alkyl, cyclobutyl, CH2-NH-C(O)-, piperazine or is absent.

5. A compound according to any preceding claim, in which **R^{14}** is -$C_{1\text{-}6}$ alkyl, -$C_{2\text{-}6}$ alkenyl, -$C_{2\text{-}6}$ alkynyl, -C(O)-, -SO_2- or is absent, optionally in which **R^{14}** is -$C_{1\text{-}6}$ alkyl.

6. A compound according to any preceding claim, in which **R^{15}** is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -$C_{1\text{-}6}$ alkyl-NH-, -cycloalkyl-NH- or is absent; optionally in which **R^{15}** is heterocycloalkyl or is absent; further optionally in which **R^{15}** is piperazine, bridged piperazine, piperazine N-oxide, piperazine cation,







, or is absent;

optionally piperazine, 

or absent;

in which  indicates attachment to **R**^{14} and  indicates attachment to **R**^{16}.

7. A compound according to any preceding claim, in which **R**^{16} is -$C_{1\text{-}6}$ alkyl, -CH_2-C(O)-NH-, -CH_2-C(O)-, -C(O)- or is absent; and/or in which **R**^{17} is absent.

8. A compound according to any preceding claim, in which **[linker]** is selected from



,



or in which **[linker]** is selected from



in which

 indicates attachment to **[MCL-1 ligand moiety]** and

 indicates attachment to **[ligase ligand moiety].**

9. A compound according to any preceding claim, in which **[MCL-1 ligand moiety]** is of:

(a) Formula (A1):

 (A1);

(b) Formula (A2):



(A2);

(c) Formula (A3):



(A3); or

(d) Formula (A4):



(A4)

10. A compound according to any preceding claim, in which in Formula (A1) **R^{12}** is



; and/or in Formula (A4) **R^{35}** is



.

11. A compound according to any preceding claim, in which:

(a) in each of Formula (A1) and Formula (A4), one of **R^{10}** and **R^{30}** is H and the other of **R^{10}** and **R^{30}** is -C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl or naphthyl, in which the phenyl or naphthyl is optionally substituted with at least one substituent selected from halogen and C_1-C_6 alkyl; and/or

(b) in Formula (A2) **R^{31}** is -C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl or naphthyl, in which the phenyl or naphthyl is optionally substituted with at least one substituent selected from halogen and C_1-C_6 alkyl; and/or

(c) in Formula (A3) $\mathbf{R^{34}}$ is $C_{2\text{-}5}$ alkyl-O-R^{13} or -O-$C_{2\text{-}5}$ alkyl-R^{13}, in which R^{13} is phenyl or naphthyl, in which the phenyl or naphthyl is optionally substituted with at least one substituent selected from halogen and C_1-C_6 alkyl.

12. A compound according to any preceding claim, in which:

(a) $\mathbf{Z_2}$ is C and  is a double bond; and/or

(b) each $\mathbf{R^9}$ is independently -C(O)OH or -P(O)$(OH)_2$; and/or

(c) $\mathbf{R^{11}}$ is halogen; and/or

(d) each $\mathbf{R^{20}}$ is Me or -$(CH_2CH_2O)_2$Me.

13. A compound according to any preceding claim, in which the C_1-C_6 alkyl substituted with morpholine or a piperazine is  or .

14. A compound according to any preceding claim, in which **[MCL-1 ligand moiety]** is selected from:

 ,  ,



,



,



,



,





and ;

optionally in which the compound is selected from:

 Compound 36	 Compound 145
 Compound 144	 Compound 147

further optionally in which the compound is:

(a) Compound 144 or 147; or

(b) Compound 147.

15. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which [ligase ligand moiety] is:

(a) Formula (IV) or (IVa)



(IV)

or



(IVa)

in which:

each of X_1 and X_2 is independently O or S;

each of Q_1 and Q_2 is independently N or CR^5, in which at least one of Q_1 and Q_2 is N;

each of E_1, E_2, E_3 and E_4 is independently N or CR';

n is 0, 1 or 2;

L_2 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, $-OR^b$, $-NR^b_2$, or $-S(O)_2R^b$;

each R^5 is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, -CN, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b_2$; -O-**R²¹**, -NH-**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;**

each R' is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, -CN, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, $-C(O)NHCHR^b_2$, $-CHR^bNHC(O)NHR^b$, $-CHR^bNHC(O)C(halogen)_2R^b$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b_2$, $-NHS(O)_2R^b$, -**R²¹**, -O-**R²¹**, -NH-**R²¹**, -C(O)-**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;**

and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which Formula (IV) contains a single **R^{21}**;

(b) Formula (VIIa), (VIIb), (VIIc) or (VIId):



(VIIa)



(VIIb)



(VIIc)

or



(VIId)

in which:

each of X_1 and X_2 is independently O or S;

each of Q_1 and Q_2 is independently N or CR, in which at least one of Q_1 and Q_2 is N;

each of W_1, W_2 and W_3 is independently N or CR^a;

Z is O, S, or NR^e;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, $-OR^b$, $-NR^b_2$, or $-S(O)_2R^b$;

each R is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, $-CN$, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b_2$, **$-R^{21}$**, **$-O-R^{21}$**, **$-NH-R^{21}$**, **$-C(O)-R^{21}$**, **$-C(O)-NH-R^{21}$**, or **$-CH_2-NH-C(O)-R^{21}$;**

each R^a is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -$NR^b{}_2$, -$NR^bC(O)R^b$, -$NR^bC(O)OR^b$, -NO_2, -CN, -$C(O)R^b$, -$C(O)OR^b$, -$C(O)NH_2$, -$C(O)NHR^b$, -$C(O)NR^b{}_2$, -OR^b, -$OC(O)R^b$, -$OC(O)OR^b$, -$OC(O)NH_2$, -$OC(O)NHR^b$, -$OC(O)NR^b{}_2$, -SR^b, -$S(O)_2R^b$, -$S(O)_2OR^b$, -$S(O)_2NH_2$, -$S(O)_2NHR^b$, -$S(O)_2NR^b{}_2$, -**R²¹**, -O-**R²¹**, -NH-**R²¹**, -C(O)-**R²¹**, -C(O)-NH-**R²¹**, or -CH_2-NH-C(O)-**R²¹;** and;

each R^e is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, -**R²¹**, -O-**R²¹**, -NH-**R²¹**, -C(O)-**R²¹**, -C(O)-NH-**R²¹**, or -CH_2-NH-C(O)-**R²¹;**

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R²¹** is a bond connected to **R¹⁸** of the linker, and in which each of Formula (VIIa), Formula (VIIb) and Formula (VIIc) contains a single **R²¹;**

(c) Formula (VIII):



(VIII)

in which

each of X_1 and X_2 is independently O or S;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -$C(O)R^b$, -$C(O)OR^b$, -$C(O)NH_2$, -$C(O)NHR^b$, -$C(O)NR^b{}_2$, -OR^b, -$NR^b{}_2$, or -$S(O)_2R^b$;

each of R_1, R_2 and R_3 is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -$NR^b{}_2$, -$NR^bC(O)R^b$, -$NR^bC(O)OR^b$, -NO_2, -CN, -$C(O)R^b$, -$C(O)OR^b$, -$C(O)NH_2$, -$C(O)NHR^b$, -$C(O)NR^b{}_2$, -OR^b, -$OC(O)R^b$, -$OC(O)OR^b$, -$OC(O)NH_2$, -$OC(O)NHR^b$, -$OC(O)NR^b{}_2$, -SR^b , $S(O)_2R^b$, -$S(O)_2OR^b$, -$S(O)_2NH_2$, -$S(O)_2NHR^b$, -$S(O)_2NR^b{}_2$, -**R²¹**, -O-**R²¹**, -NH-**R²¹**, -C(O)-**R²¹**, -C(O)-NH-**R²¹**, or -CH_2-NH-C(O)-**R²¹**; and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R²¹** is a bond connected to **R¹⁸** of the linker, and in which Formula (VIII) contains a single **R²¹;** or

(d) Formula (IX):



(IX)

in which

each of X_1 and X_2 is independently O or S;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OR^b, -N$R^b{}_2$, or -S(O)$_2R^b$;

each of Q_1, Q_2, Q_3, Q_4 and Q_5 is independently N or CR, in which at least one of Q_1, Q_2, Q_3, Q_4 and Q_5 is N;

each R is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NR^bC(O)R^b, -NR^bC(O)OR^b, -NO_2, -CN, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OR^b, -OC(O)R^b, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SR^b, -S(O)$_2R^b$, -S(O)$_2$OR^b, -S(O)$_2NH_2$, -S(O)$_2$NHR^b, or -S(O)$_2$N$R^b{}_2$, -**R^{21}**, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21}**; and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which Formula (IX) contains a single **R^{21};**

in which **[MCL-1 ligand moiety]** is a compound of Formula (A1), (A2), (A3) or (A4):



(A1)



(A2)



(A3)

or



(A4)

in which

 is a single bond or a double bond;

each $\mathbf{Z_2}$ is independently N or C, in which when $\mathbf{Z_2}$ is N, then  is a single bond; and when $\mathbf{Z_2}$ is C, then  is a double bond**;**

each $\mathbf{R^9}$ is independently -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

each $\mathbf{R^{11}}$ is independently H, halogen or C_1-C_6 alkyl,

$\mathbf{R^8}$ is C_1-C_6 alkyl substituted with a piperazine;

in each of Formula (A1) and Formula (A4), one of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is H and the other of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

$\mathbf{R^{12}}$ is  ,  ,  or  ,

each $\mathbf{R^{33}}$ is independently H, $\mathbf{R^{19}}$, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

$\mathbf{R^{31}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6

alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

each **R[32]** is independently H, 



in which **R[20]** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or  , in which p is 1-5;

R[34] is C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the

tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

R^{35} is  or  ; and

R^{19} is a bond connected to **R^{14}** of the linker, in which each of Formula (A1), Formula (A2), Formula (A3) and Formula (A4) contains a single **R^{19};**and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R^{14} is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R^{15} is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R^{16} is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R^{18} is -C_{1-6} alkyl, -C_{1-6} alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

16. A compound according to Claim 15, in which

R^{16} is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

R[18] is -C_{1-6} alkyl, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent; optionally in which **[linker]** is



or

in which

 indicates attachment to [MCL-1 ligand moiety] and

 indicates attachment to [ligase ligand moiety].

17. A compound according to Claim 15 or 16, in which **[MCL-1 ligand moiety]** is



18. A compound according to Claim 16 or 17, in which:

(a) **[ligase ligand moiety]** is:

 ;

optionally in which the compound is



Compound 146

or

(b) **[ligase ligand moiety]** is:



;

optionally in which the compound is



Compound 148.

19. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:

(a) Formula (Va) or (Vb):



(Va)

or



(Vb)

or a pharmaceutically acceptable salt or tautomer thereof,

in which

each of X_1 and X_2 is independently O or S;

Z_1 is O, S or NR^6;

T is is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

each of Y_5, Y_6, Y_7, and Y_8 is independently N or CR^7,

in which at least one of Y_5, Y_6 and Y_7 in Formula (Va) is CR^7, and at least one of Y_5, Y_5 and Y_8 in Formula (Vb) is CR^7;

n is 0, 1 or 2;

L_3 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)R'‘‘‘, -CH_2C(O)OR'‘‘‘, -C(O)OR'‘‘‘, -C(O)NH_2, -C(O)NHR'‘‘‘, -C(O)NR'‘‘‘$_2$, -OR'‘‘‘, -NR'‘‘‘$_2$, or
-$S(O)_2$R'‘‘‘;

each R^7 is independently hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, -NHR''', -NR'''$_2$, $-CH_2NR'''_2$, -NR'''C(O)R''', $-NR'''C(O)CH_2NR'''_2$, $-NR'''C(O)CH_2$-heterocycloalkyl, $-NR'''C(O)CH(OH)R'''$, $-CH_2NR'''C(O)OR'''$, -NR'''C(O)OR''', -NR'''SO_2R''', $-NO_2$, -CN, -C(O)R''', -C(O)OR''', $-C(O)NH_2$, -C(O)NHR''', -C(O)NR'''$_2$, -OR''', -OC(O)R''', -OC(O)OR''', $-OC(O)NH_2$, -OC(O)NHR''', -OC(O)NR'''$_2$, --NHC(S)NHR''', SR''', or $-S(O)_2$R''',$-S(O)_2$OR''', $-S(O)_2NH_2$, $-S(O)_2$NHR''', $-S(O)_2$NR'''$_2$, -O-**R²¹**, -NH-**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;**

each R'''' is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^6 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, -NHR''', -NR'''$_2$, -NR'''C(O)R''', $-N[C(O)R''']_2$, -NR'''C(O)OR''', $-NO_2$, -CN, -C(O)R''', -C(O)OR''', $-C(O)NH_2$, -C(O)NHR''', -C(O)NR'''$_2$, -OR''', -OC(O)R''', -OC(O)OR''', $-OC(O)NH_2$, -OC(O)NHR''', -OC(O)NR'''$_2$, -SR''', or $-S(O)_2$R''',$-S(O)_2$OR''', $-S(O)_2NH_2$, $-S(O)_2$NHR''', $-S(O)_2$NR'''$_2$, -**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;**

in which **R²¹** is a bond connected to **R¹⁸** of the linker, and in which formula (Va) and formula (Vb) each contain a single **R²¹**;

in which when Z_1 is O, then Y_6 is CR^7 and

in which when the compound is of Formula (Va), then

(i) when each of Y_5, Y_6 and Y_7 is CR^7, then at least one of R^7 is not H;

(ii) when Z_1 is NR^6, then Y_6 and Y_7 are CR^7;

(iii) when Z_1 is S, then Y_5 is not C-OMe and Y_6 is not C-OMe;

(iv) when Z_1 is S and Y_5 is C-NHCOMe, then Y_7 is not C-CH_2NR'''C(O)OR''';

(v) when Z_1 is S and Y_5 is N, then Y_6 is not C-H, C-aryl or C-C(O)OR'''; and

(vi) when Z_1 is S and Y_6 is N, then Y_7 is C-NH_2, C-NHR’‘‘, C-$NR’‘‘_2$, C-NR’‘‘C(O)OR’‘‘, C-CH_2NR’‘‘C(O)OR’‘‘, C-haloalkyl, C-^{t}Butyl, C-OR’‘‘, C-COOR’‘‘ or C-SR’‘‘; in which when Y_7 is C-NH_2, C-NHR’‘‘ or C-$NR’‘‘_2$, then Y_5 is C-H;

and when the compound is of Formula (Vb), then:

(vii) when each of Y_5, Y_6 and Y_8 is CR^7, then at least one of R^7 is not H;

(viii) when Z_1 is S, then Y_5 is not C-COOH or C-NHC(O)Me, and Y_8 is not C-Br;

(ix) when Z_1 is S and Y_6 is C-Br, then Y_8 is C-OR’‘‘

(x) when Z_1 is S, Y_5 is N and Y_6 is C-H or C-NH_2, then Y_8 is not C-H

(xi) when Z_1 is S and Y_5 is N, then Y_6 is not C- halogen, C-alkyl, C-cycloalkyl, C-aryl, C-heteroaryl, C-CH_2NH_2, C-COOalkyl, or C-NHC(O)alkyl; (xii) when Z_1 is NR^6, then Y_5, Y_6 and Y_8 are CR^7.

or

(b) Formula (IIa) or (IIb):



or



(IIa) (IIb)

in which

each of X_1 and X_2 is independently O or S;

Z is O, S or NR^2;

T is C=O or SO_2;

Y_3 is N or CR;

Y_4 is N or CR;

 indicates a single or double bond, in which

when each  is a double bond, each of W_1, W_2, W_3 and W_4 is independently N or CR^a, in which at least one of W_1, W_2, W_3 and W_4 is N, and

when each  is a single bond, W_1, W_2, W_3 and W_4 are each CR^a_2 and Y_4 is CR;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h_2$, $-OR^h$, $-NR^h_2$, or $-S(O)_2R^h$;

each R is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h_2$, $-NR^hC(O)R^h$, $-NR^hC(O)CH_2R^h$, $-NR^hC(O)CH(OH)R^h$, $-NR^hC(O)OR^h$, $-NR^hSO_2R^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h_2$, $-SR^h$, or $-S(O)_2R^h$,$-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, or $-S(O)_2NR^h_2$;

each R^a is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h_2$, $-NR^hC(O)R^h$, $-NR^hC(O)CH(OH)R^h$, $-NR^hC(O)OR^h$, $-NR^hSO_2R^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h_2$, $-SR^h$, $-S(O)_2R^h$, $-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, $-S(O)_2NR^h_2$, -O-$\mathbf{R^{21}}$, -NH-$\mathbf{R^{21}}$, -C(O)-NH-$\mathbf{R^{21}}$, or $-CH_2$-NH-C(O)-$\mathbf{R^{21}}$;

each R^h is independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^2 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h_2$, $-NR^hC(O)R^h$, $-N[C(O)R^h]_2$, $-NR^hC(O)OR^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h_2$, $-SR^h$, $-S(O)_2R^h$,$-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, or $-S(O)_2NR^h_2$; and

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

$\mathbf{R^{21}}$ is a bond connected to $\mathbf{R^{18}}$ of the linker, and in which formula (IIa) and formula (IIb) each contain a single $\mathbf{R^{21}}$;

in which when each  is a double bond, Z is NR^2, R^2 is hydrogen, and each R^a is hydrogen, then W_4 is CR^a;

in which **[MCL-1 ligand moiety]** is a compound of Formula (A1), (A2), (A3) or (A4):



(A1)



(A2)



(A3)

or



(A4)

in which



is a single bond or a double bond;

each $\mathbf{Z_2}$ is independently N or C, in which when $\mathbf{Z_2}$ is N, then  is a single bond; and when $\mathbf{Z_2}$ is C, then  is a double bond**;**

each $\mathbf{R^9}$ is independently -C(O)OH, -C(O)OC_1-C_6 alkyl, -$C(O)NH_2$ or -$P(O)(OH)_2$,

each $\mathbf{R^{11}}$ is independently H, halogen or C_1-C_6 alkyl,

$\mathbf{R^8}$ is C_1-C_6 alkyl substituted with a piperazine;

in each of Formula (A1) and Formula (A4), one of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is H and the other of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13} , -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13} , in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R^{12} is  ,  ,  or  ,

each **R^{33}** is independently H, **R^{19}**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R^{31} is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

each **R^{32}** is independently H,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,


,

,

,

,

or

, in which **R[20]** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or

, in which p is 1-5;

R[34] is C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

R[35] is

or

; and

R[19] is a bond connected to **R[14]** of the linker, in which each of Formula (A1), Formula (A2), Formula (A3) and Formula (A4) contains a single **R[19];**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R[14] is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R[15] is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -C_{1-6} alkyl, -C_{1-6} alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

20. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:

(a) Formula (VIa) or (VIb):



(VIa) (VIb)

in which

M is O, S or NH, or is absent;

 indicates attachment to **R[18]** of the linker;

R[22] is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl; and

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl

(b) Formula (II):



(II)

in which:

each of X_1 and X_2 is independently O or S;

T is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

n is 0, 1 or 2;

L_4 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, -C(O)R^b,-C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OH, -OR^b, -NH_2, -NHR^b, -NR^b_2, -S(O)$_2$H or -S(O)$_2R^b$;

R^y is selected from



in which  indicates attachment to T,

Z_3 is O, S or NR^3;

U is O, S, NR^b or CR^i_2;

each of Y_1, Y_2 and Y_3 is independently N or CR^d;

each R^d is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NHC(O)R^b$, $-NR^bC(O)R^b$, $NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $C(O)R^b$, -C(O)OH, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$,-OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-NH-**R^{21}**, or $-CH_2$-NH-C(O)-**R^{21};**

each R^i is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NHC(O)R^b$, $-NR^bC(O)R^b$, $-NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $C(O)R^b$, -C(O)OH, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$,-OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, or $-S(O)_2NR^b{}_2$**;**

each R^3 is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NHC(O)R^b$, $-NR^bC(O)R^b$, $NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $C(O)R^b$, -C(O)OH, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$,-OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, -**R^{21}**, -C(O)-NH-**R^{21}**, or $-CH_2$-NH-C(O)-**R^{21};**

each R^b is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^{21} is a bond connected to **R^{18}** of the linker, in which Formula (II) contains a single **R^{21};**

in which,

(i) when R^y is  then Y_2 is CR^d; and

(ii) when R^y is  , then R^i in CR^i_2 is not hydrogen

or

(c) Formula (III):



(III)

in which:

each of X_1 and X_2 is independently O or S;

T is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

n is 0, 1 or 2;

L_1 is hydrogen, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, -C(O)R^b,-C(O)OH, -C(O)OR^b, -CH_2C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OH, -OR^b, -NH_2, -NHR^b, -NR^b_2, -S(O)$_2$H or -S(O)$_2R^b$;

R^x is selected from



in which ~ indicates attachment to T,

Z_4 is O, S or NR^4;

V is CR^f_2, NR^4 or S;

each of G_1, G_2, G_3 and G_4 is independently N or CR^c,

each of Y_1 and Y_2 is independently N or CR^f,

each R^f is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, fused aryl-cycloalkyl, fused aryl-heterocycloalkyl, heteroaryl, heteroaryl substituted with at least one aryl group, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b_2$, $-NHC(O)R^b$, $-NR^bC(O)R^b$, $-NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $-C(O)R^b$, -C(O)OH, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, -OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b_2$, -**R²¹**, -O-**R²¹**, -NH-**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;** or when Y_1 and Y_2 are CR^f then each R^f, together with the carbon atom to which it is attached, forms a 5- or 6-membered ring;

each R^c is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, aryl substituted with at least one $-OR^b$, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b_2$, $-CH_2NH_2$, $-NHC(O)R^b$, $-NR^bC(O)R^b$, $-NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b_2$, -OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b_2$, -O-**R²¹**, -NH-**R²¹**, -C(O)-NH-**R²¹**, or $-CH_2$-NH-C(O)-**R²¹;**

each R^4 is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, C(O)R^b, -C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)$NR^b{}_2$, -OH, -OR^b, -NH_2, -NHR^b, -$NR^b{}_2$, -$S(O)_2H$, -$S(O)_2R^b$, - **R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};** and

each R^b is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^{21} is a bond connected to **R^{18}** of the linker, in which Formula (III) contains a single **R^{21};**

in which, when n = 2, each R^c is hydrogen, and each of G_1, G_2, G_3 and G_4 is CR^c, then $C{=}X_1$ may be replaced by CH;

and in which:

(i) when R^x is



and Z_4 is NH, then L_1 is hydrogen, -$CH_2C(O)OR^b$, or -OR^b;

(ii) when R^x is



or



, Z_4 is NR^4, Y_1 is CR^f, and Y_2 is N, then R^4 is not alkyl and at least one of R^2 and R is not H;

(iii) when R^x is



, Z_4 is NR^4, and Y_1 and Y_2 are CR^f, then at least one of G_1, G_2 and G_3 is N;

(iv) when Z_4 is NR^4, and Y_1 and Y_2 are CR^f, then R^x is not



;

(v) when R^x is



or


, Z_4 is NR^4, and Y_1 or Y_2 is N, then R^4 is not alkyl;

(vi) when R^x is



or


, then n = 1 or 2; and

(vii) when R^x is



or


, then Z_4 = O or S

in which **[MCL-1 ligand moiety]** is a compound of Formula (A1), (A2), (A3) or (A4):



(A1)
,


(A2)
,


(A3)
or



(A4)

in which

 is a single bond or a double bond;

each $\mathbf{Z_2}$ is independently N or C, in which when $\mathbf{Z_2}$ is N, then  is a single bond; and when $\mathbf{Z_2}$ is C, then  is a double bond**;**

each $\mathbf{R^9}$ is independently -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

each $\mathbf{R^{11}}$ is independently H, halogen or C_1-C_6 alkyl,

$\mathbf{R^8}$ is C_1-C_6 alkyl substituted with a piperazine;

in each of Formula (A1) and Formula (A4), one of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is H and the other of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

$\mathbf{R^{12}}$ is  ,  ,  or  ,

each $\mathbf{R^{33}}$ is independently H, $\mathbf{R^{19}}$, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

$\mathbf{R^{31}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6

alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

each $\mathbf{R^{32}}$ is independently H,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , or  , in which $\mathbf{R^{20}}$ is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or  , in which p is 1-5;

R[34] is C_{2-5} alkyl-O-R^{13} or -O-C_{2-5} alkyl-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-;

R[35] is  or  ; and

R[19] is a bond connected to **R[14]** of the linker, in which each of Formula (A1), Formula (A2), Formula (A3) and Formula (A4) contains a single **R[19];**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R[14] is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R[15] is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -C_{1-6} alkyl, -C_{1-6} alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

21. A compound according to Claim 20, in which **[ligase ligand moiety]** is:

(a)


or

; or


(b) (III)

optionally


or

.

22. A compound according to Claim 19, 20 or 21, in which

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

R[18] is -C_{1-6} alkyl, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent;

optionally in which **[linker]** is



in which

 indicates attachment to **[MCL-1 ligand moiety]** and

 indicates attachment to **[ligase ligand moiety].**

23. A compound according to any one of Claims 19 to 22, in which **[MCL-1 ligand moiety]** is



; optionally in which the compound is



Compound 25

24. A compound of formula (I)

[MCL-1 ligand moiety] – linker – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:









or

in which

M is O, S or NH, or is absent;

 indicates attachment to **R[18]** of the linker;

R[22] is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl; and

R[29] is hydrogen or Me

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl;

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

R^8 is H, **R^{19}**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R^9 is -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

one of **R^{10}** and **R^{30}** is H and the other of **R^{10}** and **R^{30}** is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R^{11} is H, halogen or C_1-C_6 alkyl,

R^{12} is H, 


,

,

,

,

,

,

,

,

,

,

,

,

5 ,

or , in which **R^{20}** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), or -CH_2-O-bromobenzaldehyde, in which p is 1-5;

or when **R[12]** is  and **R[10]** is -O-naphthyl substituted with -O- or -S-, then **R[20]** is  , in which  indicates attachment to -O- or -S- of **R[10]**;

and in which

R[19] is a bond connected to **R[14]** of the linker;

Z_2 is N or C, in which when **Z_2** is N, then  is a single bond; and when **Z_2** is C, then  is a double bond,

and in which Formula (A) contains a single **R[19];**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R[14] is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R[15] is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -C_{1-6} alkyl-C(O)-, cycloalkyl or -CH_2-NH-C(O)-.

25. A compound according to Claim 24, in which **[ligase ligand moiety]** is

 ,  or  .

26. A compound according to Claim 24 or 25, in which

R^{16} is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

R^{18} is cycloalkyl or -CH_2-NH-C(O)-; optionally in which **R^{18}** is cyclobutyl.

27. A compound according to Claim 24, 25 or 26, in which **R^{14}** is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C(O)-, -SO_2- or is absent; optionally in which **R^{14}** is -C_{1-6} alkyl; and/or in which **R^{15}** is heterocycloalky; optionally piperazine,

 or  .

in which  indicates attachment to **R^{14}** and  indicates attachment to **R^{16}.**

28. A compound according to any of Claims 24 to 27, in which **R^{16}** is -C_{1-6} alkyl, -CH_2-C(O)- or -C(O)-; and/or in which **R^{17}** is absent.

29. A compound according to any of Claims 23 to 28, in which **[MCL-1 ligand moiety]** is



.

30. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:

(a) Formula (IV) or (IVa)



(IV)

or



(IVa)

in which:

each of X_1 and X_2 is independently O or S;

each of Q_1 and Q_2 is independently N or CR^5, in which at least one of Q_1 and Q_2 is N;

each of E_1, E_2, E_3 and E_4 is independently N or CR';

n is 0, 1 or 2;

L_2 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$, $-OR^b$, $-NR^b{}_2$, or $-S(O)_2R^b$;

each R^5 is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, -

NO_2, -CN, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OR^b, -OC(O)R^b, -OC(O)OR^b,
-OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SR^b, -S(O)$_2R^b$, -S(O)$_2$OR^b, -S(O)$_2NH_2$,
-S(O)$_2$NHR^b, -S(O)$_2$N$R^b{}_2$; -O-**R^{21}**, -NH-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};**

each R' is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NR^bC(O)R^b, -NR^bC(O)OR^b, -NO_2, -CN, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -C(O)NHC$HR^b{}_2$, -CHR^bNHC(O)NHR^b, -CHR^bNHC(O)C(halogen)$_2R^b$, -OR^b, -OC(O)R^b, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SR^b, -S(O)$_2R^b$, -S(O)$_2$OR^b, -S(O)$_2NH_2$, -S(O)$_2$NHR^b, -S(O)$_2$N$R^b{}_2$, -NHS(O)$_2R^b$, -**R^{21}**, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};**

and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which Formula (IV) contains a single **R^{21}**;

(b) Formula (VIIa), (VIIb), (VIIc) or (VIId):



(VIIa)



(VIIb)



(VIIc)

or



(VIId)

in which:

each X_1 and X_2 is independently O or S;

each Q_1 and Q_2 is independently N or CR, in which at least one of Q_1 and Q_2 is N;

each of W_1, W_2 and W_3 is independently N or CR^a;

Z is O, S, or NR^e;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$, $-OR^b$, $-NR^b{}_2$, or $-S(O)_2R^b$;

each R is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, -CN, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, $-\mathbf{R^{21}}$, $-O-\mathbf{R^{21}}$, $-NH-\mathbf{R^{21}}$, $-C(O)-\mathbf{R^{21}}$, $-C(O)-NH-\mathbf{R^{21}}$, or $-CH_2-NH-C(O)-\mathbf{R^{21}}$;

each R^a is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, -CN, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, $-\mathbf{R^{21}}$, $-O-\mathbf{R^{21}}$, $-NH-\mathbf{R^{21}}$, $-C(O)-\mathbf{R^{21}}$, $-C(O)-NH-\mathbf{R^{21}}$, or $-CH_2-NH-C(O)-\mathbf{R^{21}}$; and;

each R^e is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, $-\mathbf{R^{21}}$, $-O-\mathbf{R^{21}}$, $-NH-\mathbf{R^{21}}$, $-C(O)-\mathbf{R^{21}}$, $-C(O)-NH-\mathbf{R^{21}}$, or $-CH_2-NH-C(O)-\mathbf{R^{21}}$;

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which $\mathbf{R^{21}}$ is a bond connected to $\mathbf{R^{18}}$ of the linker, and in which each of Formula (VIIa), Formula (VIIb) and Formula (VIIc) contains a single $\mathbf{R^{21}}$;

(c) Formula (VIII):



(VIII)

in which

each of X_1 and X_2 is independently O or S;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OR^b, -NR^b_2, or -S(O)$_2R^b$;

each of R_1, R_2 and R_3 is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -NR^b_2, -NR^bC(O)R^b, -NR^bC(O)OR^b, -NO_2, -CN, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OR^b, -OC(O)R^b, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)NR^b_2, -SR^b , S(O)$_2R^b$, -S(O)$_2OR^b$, -S(O)$_2NH_2$, -S(O)$_2NHR^b$, -S(O)$_2NR^b_2$, -**R^{21}**, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21}**; and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which Formula (VIII) contains a single **R^{21};** or

(d) Formula (IX):



(IX)

in which

each of X_1 and X_2 is independently O or S;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OR^b, -NR^b_2, or -S(O)$_2R^b$;

each of Q_1, Q_2, Q_3, Q_4 and Q_5 is independently N or CR, in which at least one of Q_1, Q_2, Q_3, Q_4 and Q_5 is N;

each R is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -NR^b_2, -NR^bC(O)R^b, -NR^bC(O)OR^b, -NO_2, -CN, -C(O)R^b, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)NR^b_2, -OR^b, -OC(O)R^b, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)NR^b_2, -SR^b, -S(O)$_2R^b$, -S(O)$_2OR^b$, -S(O)$_2NH_2$, -S(O)$_2NHR^b$, or -S(O)$_2NR^b_2$, -**R^{21}**, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21}**; and

each R^b is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, or benzyl;

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which Formula (IX) contains a single **R^{21};**

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

R^8 is H, **R^{19}**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R^9 is -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

one of **R^{10}** and **R^{30}** is H and the other of **R^{10}** and **R^{30}** is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R^{11} is H, halogen or C_1-C_6 alkyl,

R^{12} is H, 


,

,

,

,

,

,

,

,

,

,

,

,

,

, in which **R^{20}** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or

, in which p is 1-5;

or when **R[12]** is  and **R[10]** is -O-naphthyl substituted with -O- or -S-, then **R[20]** is  , in which  indicates attachment to -O- or -S- of **R[10]**;

and in which

R[19] is a bond connected to **R[14]** of the linker;

Z_2 is N or C, in which when **Z_2** is N, then  is a single bond; and when **Z_2** is C, then  is a double bond,

and in which Formula (A) contains a single **R[19];**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R[14] is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R[15] is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -C_{1-6} alkyl-C(O)-, cycloalkyl or -CH_2-NH-C(O)-.

31. A compound according to Claim 30, in which **[ligase ligand moiety]** is Formula (IV):



or



(IV) (IVa).

32. A compound according to Claim 30 or 31, in which each R' is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^b$, $-NR^b{}_2$, $-NR^bC(O)R^b$, $-NR^bC(O)OR^b$, $-NO_2$, CN, $-C(O)R^b$, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$, $-OR^b$, $-OC(O)R^b$, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, $-SR^b$, $-S(O)_2R^b$, $-S(O)_2OR^b$, $S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, $-\mathbf{R^{21}}$, $-O-\mathbf{R^{21}}$, $-NH-\mathbf{R^{21}}$, $-C(O)-\mathbf{R^{21}}$, $-C(O)-NH-\mathbf{R^{21}}$, or $-CH_2-NH-C(O)-\mathbf{R^{21}}$; optionally in which each R^b is independently hydrogen, alkyl, cycloalkyl, or aryl; further optionally in which the aryl is substituted with one or more groups selected from halogen, alkyl and O-haloalkyl, optionally in which the halogen is Cl, the alkyl is methyl and the O-haloalkyl is $O-CF_3$.

33. A compound according to Claim 30, 31 or 32, in which:

(a) one of E_1, E_2, E_3 and E_4 is N, and the remaining three of E_1, E_2, E_3 and E_4 are each CR'; optionally in which:

(i) E_1 is N, and E_2, E_3 and E_4 are CR'; or

(ii) E_2 is N, and E_1, E_3 and E_4 are CR'; or

(iii) E_3 is N, and E_1, E_2 and E_4 are CR'; or

(iv) E_4 is N, and E_1, E_2 and E_3 are CR'; or

(b) E_1, E_2, E_3 and E_4 are each CR', optionally in which E_1, E_2, E_3 and E_4 are each CH; or in which three of E_1, E_2, E_3 and E_4 are CH, and one of E_1, E_2, E_3 and E_4 is C-halogen, C-alkyl, C-alkenyl, C-alkynyl, C-aryl, C-heteroaryl, C-benzyl, C-haloalkyl, C-haloalkenyl, $C-NH_2$, $C-NHR^b$, $C-NR^b{}_2$, $C-NR^bC(O)R^b$, $C-NR^bC(O)OR^b$, $C-NO_2$, C-CN, $C-C(O)R^b$, $C-C(O)OR^b$, $C-C(O)NH_2$, $C-C(O)NHR^b$, $C-C(O)NR^b{}_2$, $C-C(O)NHCHR^b{}_2$, $C-CHR^bNHC(O)NHR^b$, $C-CHR^bNHC(O)C(halogen)_2R^b$, $C-OR^b$, $C-OC(O)R^b$, $C-OC(O)OR^b$, $C-OC(O)NH_2$, $C-OC(O)NHR^b$, $C-OC(O)NR^b{}_2$, $C-SR^b$, $C-S(O)_2R^b$, $C-S(O)_2OR^b$, $C-S(O)_2NH_2$, $C-S(O)_2NHR^b$, $C-S(O)_2NR^b{}_2$, $C-NHS(O)_2R^b$, $-\mathbf{R^{21}}$, $-O-\mathbf{R^{21}}$, $-NH-\mathbf{R^{21}}$, $-C(O)-\mathbf{R^{21}}$, $-C(O)-NH-\mathbf{R^{21}}$, or $-CH_2-NH-C(O)-\mathbf{R^{21}}$;

further optionally in which:

(i) E_2, E_3 and E_4 are each CH; or

(ii) E_1, E_3 and E_4 are each CH; or

(iii) E_1, E_2 and E_4 are each CH; or

(c) two of E_1, E_2, E_3 and E_4 are N, and the remaining two of E_1, E_2, E_3 and E_4 are each CR'; or

(d) three of E_1, E_2, E_3 and E_4 are N, and the remaining one of E_1, E_2, E_3 and E_4 is CR'.

34. A compound according to any of Claims 30 to 33, in which:

(a) Q_1 is N and Q_2 is CR; or

(b) Q_1 is N and Q_2 is N; or

(c) Q_1 is CR and Q_2 is N, optionally in which Q_1 is C-H or C-alkyl, further optionally in which Q_1 is C-H or C-Me.

35. A compound according to any of Claims 30 to 34, in which:

R^{16} is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent;

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

R^{18} is cycloalkyl or -CH_2-NH-C(O)-; optionally in which **R^{18}** is -CH_2-NH-C(O)-.

36. A compound according to any of Claims 30 to 35, in which **R^{14}** is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C(O)-, -SO_2- or is absent; optionally in which **R^{14}** is -C_{1-6} alkyl; and/or in which **R^{15}** is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C_{1-6} alkyl-NH-, -cycloalkyl-NH- or is absent; optionally in which **R^{15}** is heterocycloalkyl or is absent; further optionally in which **R^{15}** is piperazine.

37. A compound according to any of Claims 30 to 36, in which **R^{16}** is -C(O)-; and/or in which **R^{17}** is absent.

38. A compound according to any of Claims 30 to 37, in which **[linker]** is



in which

 indicates attachment to **[MCL-1 ligand moiety]** and

 indicates attachment to **[ligase ligand moiety]**.

39. A compound according to any of Claims 30 to 38, in which **[MCL-1 ligand moiety]** is:



; optionally in which the compound is selected from:

	
Compound 5	Compound 6

	
Compound 146	Compound 148

further optionally in which the compound is selected from:

	
Compound 6	Compound 146

 Compound 148	

or in which the compound is



Compound 6

40. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:

(a) Formula (Va) or (Vb):



or



(Va) (Vb)

or a pharmaceutically acceptable salt or tautomer thereof,

in which

each of X_1 and X_2 is independently O or S;

Z_1 is O, S or NR^6;

T is is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

each of Y_5, Y_6, Y_7, and Y_8 is independently N or CR^7,

in which at least one of Y_5, Y_6 and Y_7 in Formula (Va) is CR^7, and at least one of Y_5, Y_5 and Y_8 in Formula (Vb) is CR^7;

n is 0, 1 or 2;

L_3 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)R'‘‘, -CH_2C(O)OR'‘‘, -C(O)OR'‘‘, -$C(O)NH_2$, -C(O)NHR'‘‘, -C(O)NR'‘‘$_2$, -OR'‘‘, -NR'‘‘$_2$, or
-$S(O)_2$R'‘‘;

each R^7 is independently hydrogen, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR'‘‘,
-NR'‘‘$_2$, -CH_2NR'‘‘$_2$, -NR'‘‘C(O)R'‘‘, -NR'‘‘C(O)CH_2NR'‘‘$_2$, -NR'‘‘C(O)CH_2-heterocycloalkyl,
-NR'‘‘C(O)CH(OH)R'‘‘, -CH_2NR'‘‘C(O)OR'‘‘, -NR'‘‘C(O)OR'‘‘, -NR'‘‘SO_2R'‘‘, -NO_2, -CN,
-C(O)R'‘‘, -C(O)OR'‘‘, -$C(O)NH_2$, -C(O)NHR'‘‘, -C(O)NR'‘‘$_2$, -OR'‘‘, -OC(O)R'‘‘, -OC(O)OR'‘‘, -$OC(O)NH_2$, -OC(O)NHR'‘‘, -OC(O)NR'‘‘$_2$, --

NHC(S)NHR’‘‘, SR’‘‘, or -$S(O)_2$R’‘‘,-$S(O)_2$OR’‘‘, -$S(O)_2NH_2$, -$S(O)_2$NHR’‘‘, -$S(O)_2$NR’‘‘$_2$, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};**

each R’‘‘‘ is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^6 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR’‘‘, -NR’‘‘$_2$, -NR’‘‘C(O)R’‘‘, -N[C(O)R’‘‘]$_2$, -NR’‘‘C(O)OR’‘‘, -NO_2, -CN, -C(O)R’‘‘, -C(O)OR’‘‘, -C(O)NH_2, -C(O)NHR’‘‘, -C(O)NR’‘‘$_2$, -OR’‘‘, -OC(O)R’‘‘, -OC(O)OR’‘‘, -OC(O)NH_2, -OC(O)NHR’‘‘, -OC(O)NR’‘‘$_2$, -SR’‘‘, or -$S(O)_2$R’‘‘,-$S(O)_2$OR’‘‘, -$S(O)_2NH_2$, -$S(O)_2$NHR’‘‘, -$S(O)_2$NR’‘‘$_2$, -**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};**

in which **R^{21}** is a bond connected to **R^{18}** of the linker, and in which formula (Va) and formula (Vb) each contain a single **R^{21}**;

in which when Z_1 is O, then Y_6 is CR^7 and

in which when the compound is of Formula (Va), then

(i) when each of Y_5, Y_6 and Y_7 is CR^7, then at least one of R^7 is not H;

(ii) when Z_1 is NR^6, then Y_6 and Y_7 are CR^7;

(iii) when Z_1 is S, then Y_5 is not C-Ome and Y_6 is not C-Ome;

(iv) when Z_1 is S and Y_5 is C-NHCOMe, then Y_7 is not C-CH_2NR’‘‘C(O)OR’‘‘;

(v) when Z_1 is S and Y_5 is N, then Y_6 is not C-H, C-aryl or C-C(O)OR’‘‘; and

(vi) when Z_1 is S and Y_6 is N, then Y_7 is C-NH_2, C-NHR’‘‘, C-NR’‘‘$_2$, C-NR’‘‘C(O)OR’‘‘, C-CH_2NR’‘‘C(O)OR’‘‘, C-haloalkyl, C-^{t}Butyl, C-OR’‘‘, C-COOR’‘‘ or C-SR’‘‘; in which when Y_7 is C-NH_2, C-NHR’‘‘ or C-NR’‘‘$_2$, then Y_5 is C-H;

and when the compound is of Formula (Vb), then:

(vii) when each of Y_5, Y_6 and Y_8 is CR^7, then at least one of R^7 is not H;

(viii) when Z_1 is S, then Y_5 is not C-COOH or C-NHC(O)Me, and Y_8 is not C-Br;

(ix) when Z_1 is S and Y_6 is C-Br, then Y_8 is C-OR’‘‘

(x) when Z_1 is S, Y_5 is N and Y_6 is C-H or C-NH_2, then Y_8 is not C-H

(xi) when Z_1 is S and Y_5 is N, then Y_6 is not C- halogen, C-alkyl, C-cycloalkyl, C-aryl, C-heteroaryl, C-CH_2NH_2, C-COOalkyl, or C-NHC(O)alkyl; (xii) when Z_1 is NR^6, then Y_5, Y_6 and Y_8 are CR^7.

or

(b) Formula (IIa) or (IIb):



(IIa) or (IIb)

in which

each of X_1 and X_2 is independently O or S;

Z is O, S or NR^2;

T is C=O or SO_2;

Y_3 is N or CR;

Y_4 is N or CR;

 indicates a single or double bond, in which

when each is a double bond, each of W_1, W_2, W_3 and W_4 is independently N or CR^a, in which at least one of W_1, W_2, W_3 and W_4 is N, and

when each is a single bond, W_1, W_2, W_3 and W_4 are each $CR^a{}_2$ and Y_4 is CR;

n is 0, 1 or 2;

L is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -$C(O)R^h$, -$C(O)OR^h$, -$C(O)NH_2$, -$C(O)NHR^h$, -$C(O)NR^h{}_2$, -OR^h, -$NR^h{}_2$, or -$S(O)_2R^h$;

each R is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h{}_2$, $-NR^hC(O)R^h$, $-NR^hC(O)CH_2R^h$, $-NR^hC(O)CH(OH)R^h$, $-NR^hC(O)OR^h$, $-NR^hSO_2R^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h{}_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h{}_2$, $-SR^h$, or $-S(O)_2R^h$,$-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, or $-S(O)_2NR^h{}_2$;

each R^a is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h{}_2$, $-NR^hC(O)R^h$, $-NR^hC(O)CH(OH)R^h$, $-NR^hC(O)OR^h$, $-NR^hSO_2R^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h{}_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h{}_2$, $-SR^h$, $-S(O)_2R^h$, $-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, $-S(O)_2NR^h{}_2$, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-NH-**R^{21}**, or $-CH_2$-NH-C(O)-**R^{21};**

each R^h is independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^2 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, $-NH_2$, $-NHR^h$, $-NR^h{}_2$, $-NR^hC(O)R^h$, $-N[C(O)R^h]_2$, $-NR^hC(O)OR^h$, $-NO_2$, -CN, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NH_2$, $-C(O)NHR^h$, $-C(O)NR^h{}_2$, $-OR^h$, $-OC(O)R^h$, $-OC(O)OR^h$, $-OC(O)NH_2$, $-OC(O)NHR^h$, $-OC(O)NR^h{}_2$, $-SR^h$, $-S(O)_2R^h$,$-S(O)_2OR^h$, $-S(O)_2NH_2$, $-S(O)_2NHR^h$, or $-S(O)_2NR^h{}_2$; and

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^{21} is a bond connected to **R^{18}** of the linker, and in which formula (IIa) and formula (IIb) each contain a single **R^{21}**;

in which when each  is a double bond, Z is NR^2, R^2 is hydrogen, and each R^a is hydrogen, then W_4 is CR^a;

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

R[8] is H, **R[19]**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R[9] is -C(O)OH, -C(O)OC_1-C_6 alkyl, -$C(O)NH_2$ or -$P(O)(OH)_2$,

one of **R[10]** and **R[30]** is H and the other of **R[10]** and **R[30]** is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R[11] is H, halogen or C_1-C_6 alkyl,

R[12] is H,  ,  ,  ,

 ,  ,  ,  ,

 ,



,


,


,


,




,


,


,


or , in which **R20** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or 

, in which p is 1-5;

or when **R12** is 

and **R10** is -O-naphthyl substituted with -O- or -S-, then **R20** is 

, in which 

indicates attachment to -O- or -S- of **R10**;

and in which

R19 is a bond connected to **R14** of the linker;

$\mathbf{Z_2}$ is N or C, in which when $\mathbf{Z_2}$ is N, then  is a single bond; and when $\mathbf{Z_2}$ is C, then  is a double bond,

and in which Formula (A) contains a single $\mathbf{R^{19}}$**;**

and in which **[linker]** has the following formula

$\mathbf{R^{14}\text{-}R^{15}\text{-}R^{16}\text{-}R^{17}\text{-}R^{18}}$

in which

$\mathbf{R^{14}}$ is -$C_{1\text{-}6}$ alkyl, -$C_{2\text{-}6}$ alkenyl, -$C_{2\text{-}6}$ alkynyl, $C_{1\text{-}6}$ alkyl-N($C_{1\text{-}6}$ alkyl)-, -C(O)-, -SO_2- or is absent

$\mathbf{R^{15}}$ is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $C_{1\text{-}6}$ alkyl-NH-, -$C_{1\text{-}6}$ alkyl-N($C_{1\text{-}6}$ alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

$\mathbf{R^{16}}$ is -$C_{1\text{-}6}$ alkyl, -C(O)-, -C(O)-$C_{1\text{-}6}$ alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

$\mathbf{R^{17}}$ is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

$\mathbf{R^{18}}$ is -$C_{1\text{-}6}$ alkyl-C(O)-, cycloalkyl or CH_2-NH-C(O)-.

41. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:

(a) Formula (VIa) or (VIb):



(VIa) (VIb)

in which

M is O, S or NH, or is absent;

 indicates attachment to **R[18]** of the linker;

R[22] is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl; and

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl

(b) Formula (II):



(II)

in which:

each of X_1 and X_2 is independently O or S;

T is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

n is 0, 1 or 2;

L_4 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, -C(O)R^b,-C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OH, -OR^b, -NH_2, -NHR^b, -N$R^b{}_2$, -S(O)$_2$H or -S(O)$_2R^b$;

R^y is selected from



in which ~ indicates attachment to T,

Z_3 is O, S or NR^3;

U is O, S, NR^b or $CR^i{}_2$;

each of Y_1, Y_2 and Y_3 is independently N or CR^d;

each R^d is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NHC(O)R^b, -NR^bC(O)R^b, NHC(O)CH(OH)R^b, -NR^bC(O)CH(OH)R^b, -NHC(O)OR^b, -NR^bC(O)OR^b, -NHSO_2R^b, -NR^bSO_2R^b, -NO_2, -CN, -C(O)H, C(O)R^b, -C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$,-OH, -OR^b, -OC(O)H, -OC(O)R^b, -OC(O)OH, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SH, -SR^b, -S(O)$_2$H, -S(O)$_2R^b$, -S(O)$_2$OH, -S(O)$_2$OR^b, -S(O)$_2$$NH_2$, -S(O)$_2NHR^b$, -S(O)$_2NR^b{}_2$, -O-$\mathbf{R^{21}}$, -NH-$\mathbf{R^{21}}$, -C(O)-NH-$\mathbf{R^{21}}$, or -$CH_2$-NH-C(O)-$\mathbf{R^{21}}$;

each R^i is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NHC(O)R^b, -NR^bC(O)R^b, -NHC(O)CH(OH)R^b, -NR^bC(O)CH(OH)R^b, -NHC(O)OR^b, -NR^bC(O)OR^b, -NHSO_2R^b, -NR^bSO_2R^b, -NO_2, -CN, -C(O)H, C(O)R^b, -C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$,-OH, -OR^b, -OC(O)H, -OC(O)R^b, -OC(O)OH, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SH, -SR^b, -S(O)$_2$H, -S(O)$_2R^b$, -S(O)$_2$OH, -S(O)$_2$OR^b, -S(O)$_2$$NH_2$, -S(O)$_2NHR^b$, or -S(O)$_2NR^b{}_2$;

each R^3 is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NHC(O)R^b, -

$NR^bC(O)R^b$, $NHC(O)CH(OH)R^b$, $-NR^bC(O)CH(OH)R^b$, $-NHC(O)OR^b$, $-NR^bC(O)OR^b$, $-NHSO_2R^b$, $-NR^bSO_2R^b$, $-NO_2$, -CN, -C(O)H, $C(O)R^b$, -C(O)OH, $-C(O)OR^b$, $-C(O)NH_2$, $-C(O)NHR^b$, $-C(O)NR^b{}_2$,-OH, $-OR^b$, -OC(O)H, $-OC(O)R^b$, -OC(O)OH, $-OC(O)OR^b$, $-OC(O)NH_2$, $-OC(O)NHR^b$, $-OC(O)NR^b{}_2$, -SH, $-SR^b$, $-S(O)_2H$, $-S(O)_2R^b$, $-S(O)_2OH$, $-S(O)_2OR^b$, $-S(O)_2NH_2$, $-S(O)_2NHR^b$, $-S(O)_2NR^b{}_2$, $-\mathbf{R^{21}}$, -C(O)-NH-$\mathbf{R^{21}}$, or $-CH_2$-NH-C(O)-$\mathbf{R^{21}}$;

each R^b is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

$\mathbf{R^{21}}$ is a bond connected to $\mathbf{R^{18}}$ of the linker, in which Formula (II) contains a single $\mathbf{R^{21}}$;

in which,

(i) when R^y is  then Y_2 is CR^d; and

(ii) when R^y is  , then R^i in $CR^i{}_2$ is not hydrogen

or

(c) Formula (III):



(III)

in which:

each of X_1 and X_2 is independently O or S;

T is C=O or SO_2;

R^1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

n is 0, 1 or 2;

L_1 is hydrogen, alkenyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, -C(O)R^b,-C(O)OH, -C(O)OR^b, -CH_2C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OH, -OR^b, -NH_2, -NHR^b, -N$R^b{}_2$, -S(O)$_2$H or -S(O)$_2R^b$;

R^x is selected from



,


,


and


in which

 indicates attachment to T,

Z_4 is O, S or NR^4;

V is $CR^f{}_2$, NR^4 or S;

each of G_1, G_2, G_3 and G_4 is independently N or CR^c,

each of Y_1 and Y_2 is independently N or CR^f,

each R^f is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, fused aryl-cycloalkyl, fused aryl-heterocycloalkyl, heteroaryl, heteroaryl substituted with at least one aryl group, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -N$R^b{}_2$, -NHC(O)R^b, -NR^bC(O)R^b, -NHC(O)CH(OH)R^b, -NR^bC(O)CH(OH)R^b, -NHC(O)OR^b, -NR^bC(O)OR^b, -NHSO_2R^b, -NR^bSO_2R^b, -NO_2, -CN, -C(O)H, -C(O)R^b, -C(O)OH, -C(O)OR^b, -C(O)NH_2, -C(O)NHR^b, -C(O)N$R^b{}_2$, -OH, -OR^b, -OC(O)H, -OC(O)R^b, -OC(O)OH, -OC(O)OR^b, -OC(O)NH_2, -OC(O)NHR^b, -OC(O)N$R^b{}_2$, -SH, -SR^b, -S(O)$_2$H, -S(O)$_2R^b$, -S(O)$_2$OH, -S(O)$_2$OR^b, -S(O)$_2$$NH_2$, -S(O)$_2NHR^b$, -S(O)$_2NR^b{}_2$, -$\mathbf{R^{21}}$, -O-$\mathbf{R^{21}}$, -NH-$\mathbf{R^{21}}$, -C(O)-NH-$\mathbf{R^{21}}$, or -$CH_2$-NH-C(O)-$\mathbf{R^{21}}$**;** or when Y_1 and Y_2 are CR^f then each R^f, together with the carbon atom to which it is attached, forms a 5- or 6-membered ring;

each R^c is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, aryl substituted with at least one –OR^b, heteroaryl, benzyl, haloalkyl, haloalkenyl, -NH_2, -NHR^b, -NR^b_2, -CH_2NH_2, -$NHC(O)R^b$, -$NR^bC(O)R^b$, -$NHC(O)CH(OH)R^b$, -$NR^bC(O)CH(OH)R^b$, -$NHC(O)OR^b$, -$NR^bC(O)OR^b$, -$NHSO_2R^b$, -$NR^bSO_2R^b$, -NO_2, -CN, -C(O)H, -$C(O)R^b$, -$C(O)OR^b$, -$C(O)NH_2$, -$C(O)NHR^b$, -$C(O)NR^b_2$, -OH, -OR^b, -OC(O)H, -$OC(O)R^b$, -OC(O)OH, -$OC(O)OR^b$, -$OC(O)NH_2$, -$OC(O)NHR^b$, -$OC(O)NR^b_2$, -SH, -SR^b, -$S(O)_2H$, -$S(O)_2R^b$, -$S(O)_2OH$, -$S(O)_2OR^b$, -$S(O)_2NH_2$, -$S(O)_2NHR^b$, -$S(O)_2NR^b_2$, -O-**R^{21}**, -NH-**R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};**

each R^4 is independently hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, benzyl, haloalkyl, haloalkenyl, -C(O)H, $C(O)R^b$, -C(O)OH, -$C(O)OR^b$, -$C(O)NH_2$, -$C(O)NHR^b$, -$C(O)NR^b_2$, -OH, -OR^b, -NH_2, -NHR^b, -NR^b_2, -$S(O)_2H$, -$S(O)_2R^b$, - **R^{21}**, -C(O)-NH-**R^{21}**, or -CH_2-NH-C(O)-**R^{21};** and

each R^b is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, or benzyl;

R^{21} is a bond connected to **R^{18}** of the linker, in which Formula (III) contains a single **R^{21};**

in which, when n = 2, each R^c is hydrogen, and each of G_1, G_2, G_3 and G_4 is CR^c, then $C=X_1$ may be replaced by CH;

and in which:

(i) when R^x is



and Z_4 is NH, then L_1 is hydrogen, -$CH_2C(O)OR^b$, or -OR^b;

(ii) when R^x is



or



, Z_4 is NR^4, Y_1 is CR^f, and Y_2 is N, then R^4 is not alkyl and at least one of R^2 and R is not H;

(iii) when R^x is



, Z_4 is NR^4, and Y_1 and Y_2 are CR^f, then at least one of G_1, G_2 and G_3 is N;

(iv) when Z_4 is NR^4, and Y_1 and Y_2 are CR^f, then R^x is not



;

(v) when R^x is



or



, Z_4 is NR^4, and Y_1 or Y_2 is N, then R^4 is not alkyl;

(vi) when R^x is



or



, then n = 1 or 2; and

(vii) when R^x is



or



, then Z_4 = O or S

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

R8 is H, **R19**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R9 is -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

one of **R10** and **R30** is H and the other of **R10** and **R30** is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R11 is H, halogen or C_1-C_6 alkyl,

R12 is H,  ,  ,  ,


,

,

,

,

,

,

,

,

,

,

,

,

, or

, in which **R[20]** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p(C_1$-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or


, in which p is 1-5; or


when **R[12]** is and **R[10]** is -O-naphthyl substituted with -O- or -S-, then


R[20] is , in which  indicates attachment to -O- or -S- of **R[10]**;

and in which

$\mathbf{R^{19}}$ is a bond connected to $\mathbf{R^{14}}$ of the linker;

$\mathbf{Z_2}$ is N or C, in which when $\mathbf{Z_2}$ is N, then  is a single bond; and when $\mathbf{Z_2}$ is C, then  is a double bond,

and in which Formula (A) contains a single $\mathbf{R^{19}}$**;**

and in which **[linker]** has the following formula

$\mathbf{R^{14}\text{-}R^{15}\text{-}R^{16}\text{-}R^{17}\text{-}R^{18}}$

in which

$\mathbf{R^{14}}$ is -$C_{1\text{-}6}$ alkyl, -$C_{2\text{-}6}$ alkenyl, -$C_{2\text{-}6}$ alkynyl, $C_{1\text{-}6}$ alkyl-N($C_{1\text{-}6}$ alkyl)-, -C(O)-, -SO_2- or is absent

$\mathbf{R^{15}}$ is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $C_{1\text{-}6}$ alkyl-NH-, -$C_{1\text{-}6}$ alkyl-N($C_{1\text{-}6}$ alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

$\mathbf{R^{16}}$ is -$C_{1\text{-}6}$ alkyl, -C(O)-, -C(O)-$C_{1\text{-}6}$ alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

$\mathbf{R^{17}}$ is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

$\mathbf{R^{18}}$ is -$C_{1\text{-}6}$ alkyl-C(O)-, cycloalkyl or CH_2-NH-C(O)-.

42. A compound according to Claim 40 or 41, in which

$\mathbf{R^{16}}$ is -$C_{1\text{-}6}$ alkyl, -C(O)-, C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

$\mathbf{R^{17}}$ is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

$\mathbf{R^{18}}$ is cycloalkyl or CH_2-NH-C(O)-.

43. A compound according to any of Claims 24 to 42, in which one of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is H and the other of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the naphthyl is optionally substituted with -O- or -S-.

44. A compound according to any of Claims 24 to 43, in which $\mathbf{R^{30}}$ is H; and/or in which $\mathbf{R^{12}}$ is H,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .

45. A compound according to any of Claims 24 to 44, in which:

(a) $\mathbf{R^{20}}$ is Me, -CH_2-O-bromobenzaldehyde, or  ; and/or

(b) $\mathbf{Z_2}$ is C and  is a double bond; and/or

(c) $\mathbf{R^{11}}$ is hydrogen or halogen.

46. A compound according to any of Claims 24 to 45, in which **[MCL-1 ligand moiety]** is:



47. A compound of formula (I)

[MCL-1 ligand moiety] – linker – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is:









or

in which

M is O, S or NH, or is absent;

 indicates attachment to **R[18]** of the linker;

R[24] is -OMe or heterocycloalkyl

R[22] is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl;

R[29] is hydrogen or Me; and

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl;

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

R[8] is H, **R[19]**, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

R[9] is -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

one of **R[10]** and **R[30]** is H and the other of **R[10]** and **R[30]** is -C_{2-5} alkyl-O-R^{13}, -O-C_{2-5} alkyl-R^{13} or -C_{2-5} alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R[11] is H, halogen or C_1-C_6 alkyl,

R[12] is H,  ,  ,  ,

 ,  ,  ,  ,

 ,



,


,


,


,




,


,


,


or , in which **R20** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), or -CH_2-O-bromobenzaldehyde, in which p is 1-5;



or when **R12** is and **R10** is -O-naphthyl substituted with -O- or -S-,



then **R20** is , in which b indicates attachment to -O- or -S- of **R10**;

and in which

R19 is a bond connected to **R14** of the linker;

Z2 is N or C, in which when **Z2** is N, then is a single bond; and when **Z2** is C, then is a double bond,

and in which Formula (A) contains a single **R^{19};**

and in which **[linker]** has the following formula

R^{14}-R^{15}-R^{16}-R^{17}-R^{18}

in which

R^{14} is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R^{15} is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R^{16} is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R^{17} is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R^{18} is -C_{1-6} alkyl, -C_{1-6} alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

48. A compound according to Claim 47, in which **[ligase ligand moiety]** is










49. A compound according to Claim 47 or 48, in which:

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent;

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

R[18] is C_{1-6} alkyl, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent; optionally in which **R[18]** is -C1-6 alkyl, cyclobutyl, CH2-NH-C(O)-, piperazine or is absent.

50. A compound according to Claim 47, 48 or 49, in which **R[14]** is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C(O)-, -SO_2- or is absent; optionally in which **R[14]** is -C_{1-6} alkyl.

51. A compound according to any of Claims 47 to 50, in which **R**^{15} is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C_{1-6} alkyl-NH-, -cycloalkyl-NH- or is absent; optionally in which **R**^{15} is heterocycloalkyl or is absent; further optionally in which **R**^{15} is piperazine, bridged piperazine, piperazine N-oxide, piperazine cation,

















, or is absent;

optionally piperazine,  ,  or absent;

in which  indicates attachment to **R**^{14} and  indicates attachment to **R**^{16}.

52. A compound according to any of Claims 47 to 51, in which **R**^{16} is -C_{1-6} alkyl, -CH_2-C(O)-NH-, -CH_2-C(O)-, -C(O)- or is absent; and/or in which **R**^{17} is absent.

53. A compound according to any of Claims 47 to 52, in which **[linker]** is selected from



optionally in which **[linker]** is selected from



in which



indicates attachment to **[MCL-1 ligand moiety]** and



indicates attachment to **[ligase ligand moiety].**

54. A compound according to any of Claims 47 to 53, in which **[MCL-1 ligand moiety]** is selected from:



and



.

optionally in which the compound is selected from:

(a)

	
Compound 14	Compound 7

	
Compound 15	Compound 23
	
Compound 22	Compound 21

or

(b)

	
Compound 7	Compound 15

 Compound 23	 Compound 22
 Compound 21	

or

(c) Compound 22.

55. A compound of formula (I)

[MCL-1 ligand moiety] – [linker] – [ligase ligand moiety] (I)

or a salt, solvate, hydrate, isomer or prodrug thereof,

in which **[ligase ligand moiety]** is of Formula (VIa) or (VIb):



(VIa) (VIb)

in which

M is O, S or NH, or is absent;

 indicates attachment to $\mathbf{R^{18}}$ of the linker;

$\mathbf{R^{22}}$ is hydrogen, halogen, -OMe, an amino group, heterocycloalkyl, or unsubstituted C_1-C_6 alkyl; and

L' is hydrogen, alkyl, benzyl, acetyl or pivaloyl

in which **[MCL-1 ligand moiety]** is a compound of Formula (A):



(A)

in which

 is a single bond or a double bond;

$\mathbf{R^8}$ is H, $\mathbf{R^{19}}$, or C_1-C_6 alkyl optionally substituted with morpholine or a piperazine;

$\mathbf{R^9}$ is -C(O)OH, -C(O)OC_1-C_6 alkyl, -C(O)NH_2 or -P(O)$(OH)_2$,

one of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is H and the other of $\mathbf{R^{10}}$ and $\mathbf{R^{30}}$ is -$C_{2\text{-}5}$ alkyl-O-R^{13}, -O-$C_{2\text{-}5}$ alkyl-R^{13} or -$C_{2\text{-}5}$ alkyl-NMe-R^{13}, in which R^{13} is phenyl, naphthyl or tetraline, in which the

phenyl, naphthyl or tetraline is optionally substituted with at least one substituent selected from halogen, C_1-C_6 alkyl and -O(C_1-C_6 alkyl); or in which the tetraline is optionally substituted with a bridging -CH_2- group; or in which the naphthyl is optionally substituted with -O- or -S-,

R^{11} is H, halogen or C_1-C_6 alkyl,

R^{12} is H,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 

10

or  , in which **R20** is Me, -CH_2-OMe, -$(CH_2CH_2O)_p$(C_1-C_6 alkyl), -CH_2-O-bromobenzaldehyde, or  , in which p is 1-5; or

when **R12** is  and **R10** is -O-naphthyl substituted with -O- or -S-, then **R20** is  , in which  indicates attachment to -O- or -S- of **R10**;

and in which

R19 is a bond connected to **R14** of the linker;

Z2 is N or C, in which when **Z2** is N, then  is a single bond; and when **Z2** is C, then  is a double bond,

and in which Formula (A) contains a single **R19;**

and in which **[linker]** has the following formula

R14-R15-R16-R17-R18

in which

R14 is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, C_{1-6} alkyl-N(C_{1-6} alkyl)-, -C(O)-, -SO_2- or is absent

R15 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_{1-6} alkyl-NH-, -C_{1-6} alkyl-N(C_{1-6} alkyl)-, -cycloalkyl-NH-, -heterocycloalkyl-NH- or is absent

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-C_{1-6} alkyl-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, -$(CH_2O)_x$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent

x is 1-10

y is 2-10

R[18] is -C_{1-6} alkyl, -C_{1-6} alkyl-C(O)-, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent

in which at least one of R^{14}-R^{18} is present.

56. A compound according to Claim 55, in which **[ligase ligand moiety]** is:




or .

57. A compound according to Claim 55 or 56, in which

R[16] is -C_{1-6} alkyl, -C(O)-, -C(O)-NH-, -C(O)O-, -CH_2-C(O)-, -CH_2-C(O)-NH-, -CH_2-C(O)O- or is absent;

R[17] is -$CH_2(C_2H_4\text{-}O)_y$, $(C_2H_4\text{-}O)_x$, $(C_3H_6\text{-}O)_x$, or is absent; and

R[18] is -C_{1-6} alkyl, cycloalkyl, CH_2-NH-C(O)-, heterocycloalkyl, or is absent; optionally in which **R[18]** is -C_{1-6} alkyl.

58. A compound according to Claim 55, 56 or 57, in which **R[14]** is -C_{1-6} alkyl, -C_{2-6} alkenyl, -C_{2-6} alkynyl, -C(O)-, -SO_2- or is absent; optionally in which **R[14]** is -C_{1-6} alkyl; and/or in which **R[15]** is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C_{1-6} alkyl-NH-, -cycloalkyl-NH- or is absent; optionally in which **R[15]** is heterocycloalkyl or is absent; further optionally in which **R[15]** is piperazine.

59. A compound according to Claim 57 or 58, in which **R[16]** is -C(O)- and/or **R[17]** is absent.

60. A compound according to Claim 57, 58 or 59, in which **[linker]** is



.

61. A compound according to any of Claims 57 to 60, in which **[MCL-1 ligand moiety]** is



;

optionally in which the compound is:



Compound 24

62. A compound according to any preceding claim, in which T is C=O and in which X_1 and X_2 are O.

63. A compound according to any preceding claim, in which n is 1.

64. A compound according to any preceding claim, in which unless otherwise specified each alkyl, alkenyl, alkynyl, aryl, heteroaryl and benzyl is unsubstituted.

65. A compound selected from:

	
Compound 28	Compound 29

or selected from:

	
Compound 1	Compound 2
	

Compound 3	Compound 4
	
Compound 10	Compound 11
	
Compound 12	Compound 13
	
Compound 26	Compound 27

optionally in which the compound is selected from:

(a)

 Compound 1	 Compound 2
 Compound 3	 Compound 4
 Compound 10	 Compound 11

 Compound 12	 Compound 13
 Compound 26	

or

(b)

 Compound 1	 Compound 2

 Compound 3	 Compound 4
 Compound 10	 Compound 11
 Compound 12	

optionally in which the compound is Compound 12.

66. A pharmaceutical composition comprising a compound according to any preceding claim.

67. A compound according to any of Claims 1 to 65 or a pharmaceutical composition according to Claim 66, for use in medicine.

68. A compound according to any of Claims 1 to 65 or a pharmaceutical composition according to Claim 66, for use in the treatment of cancer; optionally in which the cancer is selected from breast cancer, triple negative breast cancer, colorectal cancer, pancreatic cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, small-cell lung cancer, non-small-cell lung cancer, lymphoma, non-Hodgkin's lymphoma, multiple myeloma, cervical cancer, leukaemia, chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), chronic myelogenous leukaemia (CML), acute lymphoblastic leukaemia (ALL), bladder cancer, and prostate cancer; further optionally in which the cancer is multiple myeloma acute myeloid leukaemia.

69. A combined preparation of a compound according to any of Claims 1 to 65 and at least one additional active agent, for simultaneous, separate or sequential use in therapy; optionally in which the therapy is the treatment of cancer.

70. A combined preparation according to Claim 69, in which the at least one additional active agent is an anti-cancer agent selected from eribulin; fulvestrant; midostaurin; an immune checkpoint inhibitor selected from anti-pd-1 antibody, anti-pd-l1 antibody, and anti pd-1/pd-l1 interaction inhibitor; nivolumab; pembrolizumab; atezolizumab; pidilizumab; carfilzomib; venetoclax; cytarabine; anthracyclines; a taxane compound; and hypomethylating agents.